Below you will find a growing collection of interviews with Professor Nikolai Petrovsky, a research scientist, medical doctor, and vaccine developer from Flinders University in South Australia, who in 2021 was granted registration in Iran for his COVID-19 protein-based vaccine called COVAX-19.
Professor Nikolai Petrovsky is the Director of Endocrinology (Flinders Medical Centre), Professor of Medicine (Flinders University), Vice President of the International Immunomics Society, Founder and Research Director at Vaxine and the developer of COVAX-19 and Spikogen.
- Flinders Univesity people – ARCHIVE
Professor Petrovsky will be the expert witness in the upcoming South Australian Judicial Review, to give expert testimony on behalf of the Applicants, challenging the legality of the grounds for vaccine mandate Directions, issued by the Police Commissioner under the State of Emergency.
Prof Petrovsky video interviews in reverse chronological order
2024
April 18, 2024 – Club Grubbery: Breaking: Professor Nik Petrovsky appears with his legal counsel Jay Vidanage after Federal Court refuses to prevent the closure of his research facility by direction of SA Health and Flinders University – WATCH, TWEET
- Judge orders Prof Petrovsky to exit his huge research facility in 24 hours. With current and ongoing research that is saving peoples lives, will have to just stop, and his patients will die.
- He has been targeted by the government becasue of his being an expert witness against their narrative.
2023
December 14, 2023 – Club Grubbery: Graham and John speak with Nik Petrovsky and Senator Malcolm Roberts… – WATCH
June 15, 2023 – The Chris Smith Show | TNT Radio: The Hon. Mark Latham MLC & Dr Nikolai Petrovsky on The Chris Smith Show – @28min LISTEN
“…we ourselves [Vaxine] explored an mRNA vaccine early on in this…we were intrigued on the science side, we never thought this as a serious alternative, because, as you say, there was no data whatsoever, its a very new technology no matter what anyone says, we really didn’t have the human experience with the technology that you would need.
Normally…it’s all about building up a safety portfolio for a new vaccine technology and that takes about 20 years to build.”
“We never seriously thought mRNA was going to be anything other than a science project”
“It’s never been a more dangerous time to speak the truth than during the last 3 years.“
Prof. Petrovsky [@34:50]
April 17, 2023 – BASED with Senator Alex Antic Ep #1: Nikolai Petrovsky – Australia’s Pandemic Response – WATCH
May 9, 2023 – Ask Dr. Drew: Furin Cleavage Site Is KEY To Covid’s Origin: Nikolai Petrovsky w/ Dr. Kelly Victory – WATCH, READ
2022
June 29, 2022 – Australian Medical Professionals’ Society (AMPS) Medico Legal Summit 2022 with Prof Nikolai Petrovsky – WATCH
July 26, 2022 – Petrovsky comments on FDA’s October 2021 COVID-19 vaccine formulation change – without any clinical trials – ARTICLE
“I’ve been doing vaccine development for a long time and normally regulators say the minute you change something in a formulation that may change its behaviour in a material way, you have to go back to square one and establish safety all over again, to show the change mightn’t have adverse consequences. The FDA apparently did not do this in this case,”
Why is no one questioning this? It’s the regulator’s job to act on the side of caution and assume any change could have harmful effects until proven otherwise.”
…“No-one is questioning the safety of the buffer – it’s about how it might change the properties of this particular mRNA vaccine in its lipid nanoparticles,”
…“Biologics have a trillion times more complexity than small molecule drugs, biologics can exhibit completely different properties depending on how the protein, or in this case, mRNA chain folds up. That’s why you need different FDA departments to regulate them, because the things that go wrong with biologics are much more complex than the things that go wrong with small molecule drugs,”
Professor Petrovsky
February 15, 2022 – Article referencing Covax-19 – COVID-19 vaccines: Is the spike protein “toxic” ? – READ
2021
December 20, 2021 – Maria Zeee : TGA has granted provisional determination for COVAX-19 – WATCH
December 20, 2021 – TGA grants provisional determination to Vaxine Pty Ltd for its COVID-19 recombinant protein vaccine – in relation to their COVID-19 vaccine, Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 adjuvant – READ, ARCHIVE
- “This recombinant (genetically engineered) protein vaccine will be considered for active immunisation to prevent COVID-19 caused by SARS-CoV-2. “
- “The granting of a provisional determination means that the TGA has made a decision that Vaxine Pty Ltd is now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods (ARTG).?
December 8, 2021 – ABC News: COVID-19 vaccine mandate loophole of signing up for COVAX-19 trial closed by SA government – South Australian authorities will no longer allow those participating in a vaccine trial to be exempt from state government vaccine mandates. READ
- “Adelaide-based researcher Nikolai Petrovsky’s bid for his locally-developed COVID-19 vaccine, COVAX-19, to be approved for use in Australia has raised more than $750,000.”
- But in a new direction issued today, SA Police said “taking part in a COVID-19 vaccination trial is no longer a valid reason to be exempt”.
- [TGA putting up road blocks for “traditional” like vaccine, promoting new technology vaccine platforms like mRNA!]
December 8, 2021 – JP Drake (#31) 3hr in depth interview on vaccines and Big Pharma with Nikolai Petrovsky – WATCH, LISTEN
November 8, 2021 – Zeee Media: Professor Nikolai Petrovsky – The current MRNA COVID-19 vaccines are not safe or effective – WATCH
November 19, 2021 – Trial Site News – Dr Petrovsky speaks about Australian situation – WATCH
November 16, 2021 – Trial Site News – Dr Nikolai Petrovsky Discusses His Novel Vaccine for COVID-19 – WATCH
November 5, 2021 – AFIPN report Tim Jaeger: in-depth interview with Prof Petrovsky – WATCH, Original PART 1, PART 2
October 28, 2021 – Public Forum with Prof Petrovsky – WATCH, FB
October 22, 2021 – Vaccine Adverse Events, Mandates and Secrecy in Australia with Discernable – WATCH
September 24, 2021 – Vaccine: Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection – Li, Petrovsky et al – READ
- Four researchers on the paper, including Professor N Petrovsky, are affiliated with Vaxine Pty Ltd which holds the rights to COVAX-19™ vaccine and Advax™ adjuvants.
- Part NIAID funding grant number HHS-N272201400053C
August 24, 2021 – SciMex press release: EXPERT REACTION: Modelling predicts 80 per cent adult COVID-19 vaccination won’t be enough – READ
- “The results of this modelling vary from work by the Doherty Institute that the government’s vaccination targets are based on.”
- “We need to be extremely cautious about making policy decisions based on just a single model. Such models are extremely sensitive to their inputs and assumptions, and can easily provide misleading results…” Petrovsky
- “The Doherty model is based on assumptions that the two current vaccines provide high levels of sustained protection against delta virus transmission, assumptions poorly supported by available data….”
- August 3, 2021 – EXPERT REACTION: Doherty Institute modelling shows way out of lockdowns incl Prof Booy- READ
- Re their statement “Modelling from the Doherty Institute used to set the federal government’s vaccination targets for reducing COVID-19 restrictions has been released. The modelling shows vaccination rates of 70 and 80 per cent can significantly reduce transmission, and there is a necessity to vaccinate ‘key transmitting age groups’ as a priority.”
- Doherty Modelling Report for National Cabinet 30 July 2021 – PDF
August 12, 2021 – SciMex press release: COVID-19 vaccine trials progress after safety study – READ
- “A South Australian-developed SARS-CoV-19 vaccine is preparing to progress to final stages of human clinical trials after early animal testing confirmed its safety and effectiveness in preventing COVID-19 lung infection.”
- September 24, 2021 – Vaccine: Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection – Li, Petrovsky et al – READ
June 24, 2021 – SciMex press release: EXPERT REACTION: Origin of COVID-19 remains a mystery – READ
- Scientists using computer modelling to study SARS-CoV-2… have discovered the virus is most ideally adapted to infect human cells – rather than bat or pangolin cells, again raising questions of its origin.”
- “The scientists, from Flinders University and La Trobe University, used genomic data from the 12 animal species to painstakingly build computer models of the key ACE2 protein receptors for each species. These models were then used to calculate the strength of binding of the SARS-CoV-2 spike protein to each species’ ACE2 receptor.
- Surprisingly, the results showed that SARS-CoV-2 bound to ACE2 on human cells more tightly than any of the tested animal species, including bats and pangolins. If one of the animal species tested was the origin, it would normally be expected to show the highest binding to the virus.”
June 24, 2021 – Nature: In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin– Piplani, Nikolai Petrovsky et al – READ, Rand Paul – CREDIT,
- “Spike protein exhibited the highest binding to human (h)ACE2 of all the species tested…These findings show that the earliest known SARS-CoV-2 isolates were surprisingly well adapted to bind strongly to human ACE2…”
- [This is unsusal for a virus to be so well adapted so early, its as though it was developed in a lab and perfected by running it through humanises mice]
- Jan 5, 2022 – Vision Times: Scientists Using Oracle Supercomputing Find SARS-CoV-2 Is ‘Highly Adapted’ for Humans – READ, National Pulse: Virus is ‘Highly Adapted’ for Human (Not Bat or Pangolin) Infection – READ
2020
September 3, 2020 – SciMex Press Release: Computer models for 80 potential COVID-19 treatments – READ
- Australian scientists using cloud-based supercomputer programs have joined forces with biotechnology company Vaxine Pty Ltd to identify up to 80 new potential candidate drugs against the COVID-19 virus.
- The Australian Government today announced a $1 million grant to support the Covax-19® vaccination’s progress through clinical trials. The grant, matched by Vaxine, is one of 13 early stage biomedical projects to receive funding through the Federal Government’s Biomedical Translation Bridge (BTB) program, part of Australia’s landmark Medical Research Future Fund.
September 1, 2020 – ArXiv journal pre print: Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies – Petrovsky et al – READ
July 31, 2020 – SciMex Press Release: EXPERT REACTION: South Australian COVID-19 vaccine trial clears phase 1 – READ Prof Paul Griffin who is involved with Novavax and UQ responds to nothing being published as yet-
- “A word of caution, however, in that no data has been shared, much less published in a peer-reviewed journal, which is really what is required to substantiate any claims of safety or efficacy. This should hopefully follow in the near future. It was also a rather small phase 1 study and, when talking about immune responses, only an antibody response has thus far been mentioned. And only systemic side-effects have been mentioned as not being present” Prof Griffin
- [I note that both COVID-19 mRNA vaccines were heralded “safe and effective” following simple press releases, some claims were based on an antibody response in just 8 mice!!]
June 30, 2020 – ClinicalTrials.gov: Monovalent Recombinant COVID19 Vaccine (COVAX19) – trial #NCT04453852, sponsored by Vaxine Pty Ltd – READ
- Covax-19 consists of highly purified recombinant SARS-COV-2 spike protein plus Advax-SM adjuvant in a sterile solution for intramuscular injection. COVAX-19™ vaccine is manufactured using a Sf9 platform. Advax-CpG adjuvant has previously been well tolerated and effective in trials of hepatitis B, H5N1 (NCT02335164) and H7N9 (NCT03038776) influenza vaccines and has recently been tested by the NIH in a US multicentre clinical trial with 2 quadrivalent seasonal influenza vaccines (NCT03945825).”
May 14, 2020 – SciMex Press Release: Origins of COVID-19 still a mystery by Petrovsky – READ
- ArXiv Preprint: In silico comparison of spike protein-ACE2 binding affinities across species; significance for the possible origin of the SARS-CoV-2 virus by Petrovsky et al – READ Published Nov 21, 2020
April 3, 2020 – Scimex | Press Release: Closing in on COVID-19 vaccine – READ, ARCHIVE
- “South Australian researchers working with Oracle Cloud technology and vaccine technology developed by local company Vaxine Pty Ltd are testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. The team is headed by Nikolai Petrovsky, Flinders University Professor and Research Director at Vaxine”
- “The vaccine has progressed into animal testing in the US and, once we confirm it is safe and effective, will then be advanced into human trials,” says Professor Petrovsky – stressing expectations shouldn’t be elevated until all testing is completed.
- “The latest cloud-based technology provided by Oracle enabled the team to “dramatically speed up our ability to analyse the COVID-19 virus and use this information to design the vaccine candidate”.”
- “As soon as the genomic sequence of COVID-19 became available in January, we immediately used this, combined with our previous experience in developing a SARS coronavirus vaccine, to characterise the key viral attachment molecule called the spike protein,”
- We used computer models of the spike protein and its human receptor, ACE2, to identify how the virus was infecting human cells, and then were able to design a vaccine to block this process,”
- “The team has exploited the very latest technologies, including AI, advanced manufacturing and Cloud computing to accelerate vaccine design, shaving years off normal development timeframes,” says Flinders University Associate Professor Dimitar Sajkov, a respiratory physician in South Australia
- We achieved great results with Vaxine’s swine flu vaccine developed during the 2009 swine flu pandemic, where we commenced clinical trials of a vaccine within 3 months of discovery of the virus. We hope to achieve similar results with their COVID-19 vaccine candidate when it is ready for human testing” he says.
